CD274 and small cell lung carcinoma: The proportion of the SCLC population that derives benefit from PD-1/PD-L1 inhibitors (as assessed in our analyses or by single-agent response rates) is smaller than the size of the inflamed subtype population, and at least some patients from other SCLC subtypes appear to derive benefit from these agents [61].